FGFR2 and infantile convulsions and choreoathetosis: A four-step phase I clinical trial assessed erdafitinib’s safety and tolerability, first in an unselected patient population and subsequently in patients with FGFR alterations, such as FGFR3 mutations in urothelial carcinoma and FGFR2-fusions in ICCA (33).